Sign up to save your podcasts
Or
Share Findings From NEMO, and Other Melanoma Highlights
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Findings From NEMO, and Other Melanoma Highlights
In a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber.
View all episodes
By MedscapeIn a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber.